Breast Cancer Clinical Trial
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer
Summary
RATIONALE: Imaging procedures such as positron emission tomography (PET) may improve the ability to detect the extent of breast cancer.
PURPOSE: Diagnostic trial to study the effectiveness of PET to detect the extent of breast cancer in women who have primary or recurrent breast cancer.
Full Description
OBJECTIVES:
Determine the sensitivity, specificity, and accuracy of fludeoxyglucose F 18 (FDG) positron emission tomography (PET) as compared to conventional imaging in determining the extent of disease in women with primary or recurrent breast cancer.
Determine how often clinical management and operative intervention plans for patients are altered based on these FDG-PET scan findings.
Determine whether FDG-PET results in more accurate detection of disease in these patients.
OUTLINE: Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
PROJECTED ACCRUAL: (50 with primary disease and 50 with recurrent disease) will be accrued for this study within 1-2 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Diagnosis of breast cancer for which surgical intervention is planned
Large primary breast cancer (i.e., larger than 5 cm, T3) as determined by prior biopsy, physical exam, or mammogram OR
Locally advanced breast cancer (T4) OR
Clinical suspicion of axillary nodal disease (N1-2) (i.e., stage IIB-IIIA) OR
Locally or regionally recurrent disease
No locally recurrent disease that is non-invasive (i.e., ductal carcinoma in situ)
No locally advanced disease (e.g., inflammatory breast cancer) that will be treated with neoadjuvant chemotherapy without surgery
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age:
Not specified
Sex:
Female
Menopausal status:
Not specified
Performance status:
Not specified
Life expectancy:
Not specified
Hematopoietic:
Not specified
Hepatic:
Not specified
Renal:
Not specified
Other:
No other malignancy except previously treated nonmelanoma skin cancer or carcinoma in situ of the cervix
No known active infection
No autoimmune disease or inflammatory disease (e.g., sarcoidosis or rheumatoid arthritis)
Able to fast for 6 hours and tolerate a FDG-PET scan for the duration of the test
Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
See Disease Characteristics
Endocrine therapy:
Not specified
Radiotherapy:
Not specified
Surgery:
See Disease Characteristics
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10021, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.